Breaking

March 6, 2026: Peptide Sciences — the largest gray market peptide vendor in the US — voluntarily shut down operations. What this means for your access to peptides.

Physician Clinical Brief — March 2026

After
Peptide Sciences

The gray market's biggest name just closed. A physician-authored guide to understanding what happened, which compounds are still legally accessible, and how to transition to a regulated, physician-supervised protocol.

Physician-authored
Licensed compounding pharmacy
Tualatin, Oregon
Physician Clinical Brief
After Peptide Sciences: A Physician's Guide to Safe, Legal Peptide Access in 2026
Dr. Yusuf Mathai, MD/MPH — Oregon Health DPC
What's Inside
01 What happened — the full regulatory story behind the shutdown
02 The legal landscape — Category 1 vs. Category 2 explained clearly
03 What IS available — full current compounding formulary with pricing
04 Gray market vs. prescribed — direct comparison across 8 factors
05 Your specific situation — guidance by compound type
7 pages  •  Free download Physician-Authored
$7.4M
Monthly revenue at shutdown
(Dec 2025, Grips Intelligence)
10+
Gray market vendors shut down,
raided, or prosecuted since 2024
50+
FDA warning letters issued to
GLP-1 vendors in Sept 2025
8
Compounds still available through
licensed compounding pharmacies

The Regulatory Crackdown
That Changed Everything

Peptide Sciences didn't get raided. They read the regulatory trajectory, counted their earnings, and made a rational business decision. Understanding why they left tells you everything about what comes next for gray market sourcing.

01
October 2023
FDA Designates Category 2 Peptides
BPC-157, TB-500, CJC-1295, Ipamorelin, and 13 others are banned from licensed pharmacy compounding. Gray market vendors become the only remaining source — with no quality oversight.
02
June 2025
Amino Asylum Warehouse Raided
FDA physically raids a major competitor. Website goes dark. Pending orders frozen. The enforcement era escalates from warning letters to physical seizure.
03
September 2025
50+ Warning Letters Issued
FDA issues more than 50 warning letters to GLP-1 compounders with confirmed DOJ involvement. CDER warning letters jump 50% year-over-year. The gray market's highest-margin product line collapses overnight.
04
December 2025
Criminal Guilty Pleas
Paradigm Peptides founders enter federal guilty pleas. Tailor Made Compounding pleads guilty and forfeits $1.79M. The enforcement apparatus demonstrates it will pursue criminal prosecution.
05
March 6, 2026
Peptide Sciences Goes Dark
Three sentences on a blank white page. The largest gray market peptide vendor in the US — $7.4M/month in revenue — closes voluntarily. The gray market's most credible name is gone.
"The FDA isn't killing peptides. They're killing the gray market distribution channel. The molecules aren't going away. The unregulated vendors selling them without oversight or accountability are."
Andrew Huberman, Stanford Neuroscientist — March 6, 2026

What's Still Legally
Available — and What Isn't

The picture is more nuanced than most coverage suggests. A meaningful portfolio remains accessible through a physician prescription and a licensed compounding pharmacy.

Available via Rx
Sermorelin
Growth hormone secretagogue — sleep quality, body composition, recovery. Available as injection, troche, or sublingual tablet.
Available via Rx
PT-141 (Bremelanotide)
Sexual health — libido and arousal in men and women. Physician-prescribed injection or home kit.
Available via Rx
NAD+
Cellular energy, longevity support, cognitive function. Available as injection or sublingual rapid-dissolve tablet.
Available via Rx
GHK-Cu
Skin rejuvenation, anti-aging, hair restoration. Available as nasal spray, topical solution, or topical cream with niacinamide.
Available via Rx
Semaglutide
Weight management and metabolic health. Compounded with B6 — available at a fraction of brand-name cost with physician oversight.
Available via Rx
Tirzepatide
Dual GIP/GLP-1 agonist for weight and metabolic management. Multiple forms available through licensed pharmacy.
Category 2 — Not Available
BPC-157 / TB-500
Removed from compounding formulary Oct 2023. Under review for potential reclassification — no formal FDA action yet as of March 2026.
Category 2 — Not Available
CJC-1295 / Ipamorelin
Removed from compounding formulary Oct 2023. The RFK Jr. reclassification announcement has not yet resulted in formal FDA rulemaking.

Gray Market vs.
Physician-Prescribed

Factor
Gray Market Source
Physician Rx / Licensed Pharmacy
Legal Status
SAFE Drugs Act now explicitly prohibits many products
Fully legal — 503A pharmacy + valid prescription
Product Quality
Independent testing found up to 50% underdosing at Peptide Sciences
USP sterility standards; COA on every batch
Contamination Risk
LPS contamination documented; no sterility standards enforced
USP 797 sterility required for all injectables
Medical Oversight
None — self-dosing, no labs, no monitoring
Baseline labs, dose titration, follow-up monitoring
Payment
Venmo, Zelle, crypto only — payment processors declined
Standard credit card, HSA, FSA accepted
Vendor Stability
Company may disappear overnight
Stable pharmacy with regulatory accountability

Who This Brief
Was Written For

⚗️
Former Gray Market Users
You were purchasing from Peptide Sciences, Amino Asylum, or similar vendors. Your supply just disappeared. This brief tells you exactly what's still accessible through legitimate channels.
💉
Current GLP-1 Patients
You've been managing your weight with compounded semaglutide or tirzepatide from an online vendor. Do not interrupt your protocol without guidance — both remain available through licensed pharmacy.
🔬
Optimization-Focused Patients
You've been using sermorelin, NAD+, PT-141, or other compounds and want to understand your options in the new regulatory environment — with physician oversight and confirmed quality.

Get the Full
Physician Brief

7 pages. Written by Dr. Yusuf Mathai, MD/MPH. Covers the full regulatory story, compound-by-compound availability, gray market vs. prescribed comparison, and your specific next steps.

or

Call us directly: (503) 506-8500  •  [email protected]

Dr. Yusuf Mathai
MD/MPH — Oregon Health DPC
Physician-founder, Oregon Health DPC
Hormone optimization & peptide therapy
Metabolic & performance medicine
FarmaKeio licensed pharmacy partner
Tualatin, Oregon — serving the Portland metro

Oregon Health DPC was designed for patients who take their health seriously, have done their research, and want clinical depth — not a 10-minute prescription renewal from a telehealth mill.

Our approach to peptide and optimization programs begins with a comprehensive baseline evaluation, follows with a physician-designed protocol built around your specific biology, and includes regular monitoring to verify clinical response. All compounds are dispensed from an FDA-registered compounding pharmacy with batch certificates of analysis.

If you are looking for an anonymous online checkout and a generic protocol, we are not the right fit. If you want a physician who will understand your history and build a protocol around your goals, we should talk.

Schedule a Private Assessment
This document is for educational purposes only and does not constitute medical advice or establish a physician-patient relationship. Regulatory information reflects publicly available FDA and legislative data as of March 2026 and is subject to change. Always consult a licensed healthcare provider before beginning, modifying, or discontinuing any therapeutic protocol. © 2026 Oregon Health DPC.